Rising finance costs
Finance costs are elevated due to debt-funded growth; management acknowledges the need to improve cost ratios.
medium · analyst_questionFredun Pharmaceuticals Ltd — Q4 FY26
Fredun Pharmaceuticals delivered a strong Q4 FY26 with revenue of ₹213 crore (+27% YoY), EBITDA of ₹29.1 crore (+67% YoY), and PAT of ₹11.1 crore (+56% YoY).
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Raw material price inflation
Geopolitical tensions have increased raw material costs; management mitigates with buffer stock but margins could be pressured if sustained.
medium · analyst_questionWorking capital strain from rapid growth
Fast organic growth may stretch working capital; management claims improvement but inventory remains high at ₹270 crore.
medium · data_observation